RDCA-DAP is an FDA-funded initiative that provides a centralized and standardized infrastructure to support and accelerate rare disease characterization with the goal of accelerating therapy developme
Bristol Myers Squibb erwirtschaftete 2022 einen weltweiten Umsatz von rund 18,7 Milliarden US-Dollar mit Arzneimitteln zur Behandlung Seltener Erkrankungen¹ im Therapiegebiet Onkologie. Damit war das
Additional file 5: Table S5. List of the surveyed 30 leading provincial institutions of the National Network to Collaborate on Diagnosis and Treatment of Rare Diseases in China.
